TuHURA Biosciences (NASDAQ:HURA) Releases Earnings Results

TuHURA Biosciences (NASDAQ:HURA) issued its quarterly earnings data on Friday. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01), Zacks reports.

TuHURA Biosciences Trading Down 8.0%

NASDAQ:HURA opened at $2.31 on Friday. The business’s 50-day moving average is $2.14 and its 200 day moving average is $1.61. TuHURA Biosciences has a 12 month low of $0.41 and a 12 month high of $4.05. The company has a market capitalization of $147.10 million, a P/E ratio of -3.67 and a beta of -0.01.

Institutional Investors Weigh In On TuHURA Biosciences

Several hedge funds have recently made changes to their positions in the company. Bank of America Corp DE acquired a new stake in shares of TuHURA Biosciences during the 4th quarter worth approximately $59,000. Jane Street Group LLC acquired a new position in TuHURA Biosciences during the first quarter worth $69,000. Geode Capital Management LLC raised its position in shares of TuHURA Biosciences by 111.4% during the 2nd quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock worth $1,300,000 after purchasing an additional 307,260 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in shares of TuHURA Biosciences during the second quarter valued at approximately $27,000. Finally, New York State Common Retirement Fund acquired a new position in TuHURA Biosciences in the 2nd quarter valued at $97,000. 0.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on HURA. Weiss Ratings reissued a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Tuesday, April 21st. Wall Street Zen cut shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Citizens Jmp began coverage on shares of TuHURA Biosciences in a research report on Monday, April 27th. They set a “market outperform” rating and a $9.00 price target for the company. Citigroup began coverage on shares of TuHURA Biosciences in a report on Monday, April 27th. They issued an “outperform” rating for the company. Finally, Rodman & Renshaw began coverage on TuHURA Biosciences in a report on Wednesday, April 15th. They issued a “buy” rating for the company. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.00.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.